The effect of the addition of carbogen inhalation and nicotinamide to conventional chemotherapy for hypoxia parameters in non-Hodgkin lymphoma patients

Phase 2

Completed

• Conditions: Diffuse large B-cell lymphoma; Cancer

• Registration Number: ISRCTN77237304
• Lead Sponsor: Dr. Kariadi Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-06-14
• Study Completion: 2022-05-31
• Last Update Posted: 25 July 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. DLBCL patients with increased expression of HIF-1a (>10%) via tissue immunohistochemistry
2. Do not have anemia (hemoglobin =11 g/dl)
3. Age 18-65 years
4. Do not have obstructive pulmonary disease (normal x-ray thorax and spirometry)
5. No heart problems (normal electrocardiogram (ECG) and/or normal left ventricular ejection fraction (LVEF) echocardiography)
6. Have no cerebrovascular disease
7. Do not experience severe liver function problems
8. No severe renal function impairment
9. Do not suffer from diabetes mellitus (fasting blood glucose ?126 mg/dl or random blood glucose <200 mg/dl)

Exclusion Criteria

1. Eastern Cooperative Oncology Group (ECOG) =2
2. Pregnancy before or while undergoing chemotherapy
3. History of chemotherapy for non-Hodgkin lymphoma (NHL) cases before
4. Allergic reaction to chemotherapy treatment

Study & Design

• Study Type: Interventional
• Study Design: Not specified